Literature DB >> 12416651

A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.

Eric H M Hoomans1, Bernard B Mulder.   

Abstract

PURPOSE: To compare the efficacy, efficacy and safety of a fixed daily dose of recombinant FSH (Puregon) of a 100- and 200-IU regimen in Asian women undergoing ovarian stimulation for IVF/ICSI.
METHODS: This was a prospective, randomized, double-blind, multicenter (n = 9) study. Prior to the start of rFSH, all women were pretreated with a gonadotropin releasing hormone agonist (GnRH-a) for pituitary downregulation.
RESULTS: A total of 330 women were treated with rFSH: 163 subjects with 100 IU and 167 subjects with 200 IU. In the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (9.6 vs. 5.0 oocytes, p < 0.001). The total dose rFSH needed to develop at least three follicles with a diameter of >17 mm was significantly lower in the 100 IU treatment group (1,194 vs. 2,034 IU, p < 0.001). Although more cycle cancellations were seen in the 100 IU group (24 vs. 13%), the ongoing pregnancy rate per started cycle was comparable between both groups (16.6% in the 100 IU group vs. 15.0% in the 200 IU group).
CONCLUSIONS: The use of a 100 IU fixed dose is less effective in terms of the number of oocytes retrieved and the higher cancellation rate, but more efficient as indicated by a lower total recombinant FSH dose needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416651      PMCID: PMC3455678          DOI: 10.1023/a:1020358419073

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  11 in total

1.  A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.

Authors:  H J Out; I David; R Ron-El; S Friedler; E Shalev; J Geslevich; J Dor; A Shulman; Z Ben-Rafael; B Fisch; M Dirnfeld
Journal:  Hum Reprod       Date:  2001-06       Impact factor: 6.918

2.  EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. CPMP Working Party on Efficacy of Medicinal Products.

Authors: 
Journal:  Pharmacol Toxicol       Date:  1990-10

3.  Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH.

Authors:  F Ubaldi; M Camus; J Smitz; H C Bennink; A Van Steirteghem; P Devroey
Journal:  Fertil Steril       Date:  1996-08       Impact factor: 7.329

4.  Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins.

Authors:  H J Out; S G Driessen; B M Mannaerts; H J Coelingh Bennink
Journal:  Fertil Steril       Date:  1997-07       Impact factor: 7.329

5.  The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization.

Authors:  P Devroey; H Tournaye; A Van Steirteghem; P Hendrix; H J Out
Journal:  Hum Reprod       Date:  1998-03       Impact factor: 6.918

6.  Cryopreservation: the practicalities of evaluation.

Authors:  H W Jones; H J Out; E H Hoomans; S G Driessen; H J Coelingh Bennink
Journal:  Hum Reprod       Date:  1997-07       Impact factor: 6.918

7.  Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.

Authors:  H J Out; D D Braat; B M Lintsen; T Gurgan; O Bukulmez; O Gökmen; G Keles; P Caballero; J M González; F Fábregues; J Balasch; R Roulier
Journal:  Hum Reprod       Date:  2000-01       Impact factor: 6.918

8.  Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study.

Authors:  M H van Hooff; A T Alberda; G J Huisman; G H Zeilmaker; R A Leerentveld
Journal:  Hum Reprod       Date:  1993-03       Impact factor: 6.918

9.  A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.

Authors:  H J Out; B M Mannaerts; S G Driessen; H J Bennink
Journal:  Hum Reprod       Date:  1995-10       Impact factor: 6.918

10.  High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome.

Authors:  J A Land; M I Yarmolinskaya; J C Dumoulin; J L Evers
Journal:  Fertil Steril       Date:  1996-05       Impact factor: 7.329

View more
  4 in total

Review 1.  Is there a recommended maximum starting dose of FSH in IVF?

Authors:  Luk Rombauts
Journal:  J Assist Reprod Genet       Date:  2007-06-17       Impact factor: 3.412

2.  Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.

Authors:  Dharmawijaya N Lekamge; Michelle Lane; Robert B Gilchrist; Kelton P Tremellen
Journal:  J Assist Reprod Genet       Date:  2008-10-30       Impact factor: 3.412

Review 3.  Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).

Authors:  Sarah F Lensen; Jack Wilkinson; Jori A Leijdekkers; Antonio La Marca; Ben Willem J Mol; Jane Marjoribanks; Helen Torrance; Frank J Broekmans
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

4.  Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis.

Authors:  Adrija Kumar Datta; Abha Maheshwari; Nirmal Felix; Stuart Campbell; Geeta Nargund
Journal:  Hum Reprod Update       Date:  2021-02-19       Impact factor: 15.610

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.